Immunotherapy with NK cells: recent developments in gene modification open up new avenues

被引：29
作者：
Reindl, Lisa Marie [1 ,2 ]
Albinger, Nawid [1 ,2 ]
Bexte, Tobias [1 ,2 ]
Mueller, Stephan [1 ,2 ]
Hartmann, Jessica [3 ]
Ullrich, Evelyn [1 ,2 ,4 ]
机构：
[1] Goethe Univ Frankfurt, Childrens Hosp, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Expt Immunol, Frankfurt, Germany
[3] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany
[4] Goethe Univ, Frankfurt Canc Inst, Frankfurt, Germany
来源：
ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期
关键词：
CAR; NK cells; NK-92; cells; cell therapy; NATURAL-KILLER-CELL; CHIMERIC ANTIGEN RECEPTOR; T-CELLS; MESSENGER-RNA; NK-92; CELLS; HEMATOPOIETIC-CELLS; CORD BLOOD; IN-VITRO; ADOPTIVE TRANSFER; VIVO EXPANSION;
D O I：
10.1080/2162402X.2020.1777651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
引用
收藏
页数：12
相关论文
共 120 条
  • [111] Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
    Tonn, T
    Becker, S
    Esser, R
    Schwabe, D
    Seifried, E
    [J]. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (04): : 535 - 544
  • [112] Rapid and highly efficient gene transfer into natural killer cells by nucleofection
    Trompeter, HI
    Weinhold, S
    Thiel, C
    Wernet, P
    Uhrberg, M
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 274 (1-2) : 245 - 256
  • [113] New prospects on the NKG2D/NKG2DL system for oncology
    Ullrich, Evelyn
    Koch, Joachim
    Cerwenka, Adelheid
    Steinle, Alexander
    [J]. ONCOIMMUNOLOGY, 2013, 2 (10):
  • [114] Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
    Wang, Jiao
    Lupo, Kyle B.
    Chambers, Andrea M.
    Matosevic, Sandro
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [115] WANG M, 2008, BMC GENOMICS, V9, DOI DOI 10.1186/1471-2164-9- 225
  • [116] A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
    Williams, Brent A.
    Law, Arjun Datt
    Routy, Bertrand
    denHollander, Neal
    Gupta, Vikas
    Wang, Xing-Hua
    Chaboureau, Amelie
    Viswanathan, Sowmya
    Keating, Armand
    [J]. ONCOTARGET, 2017, 8 (51) : 89256 - 89268
  • [117] Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu, Lei
    Adams, Mary
    Carter, Troy
    Chen, Roger
    Muller, George
    Stirling, David
    Schafer, Peter
    Bartlett, J. Blake
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4650 - 4657
  • [118] Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
    Xiao, Lin
    Cen, Dongzhi
    Gan, Haining
    Sung, Yan
    Huang, Nanqi
    Xiong, Hanzhen
    Jin, Qiongmei
    Su, Liqun
    Liu, Xuejuan
    Wang, Kejian
    Yan, Guangrong
    Dong, Tianfa
    Wu, Shangbiao
    Zhou, Pengzhi
    Zhang, Jinshan
    Liang, Weixiang
    Ren, Junlan
    Teng, Yaoshu
    Chen, Can
    Xu, Xue Hu
    [J]. MOLECULAR THERAPY, 2019, 27 (06) : 1114 - 1125
  • [119] You FT, 2019, AM J CANCER RES, V9, P64
  • [120] Zhang R, 2004, ONCOL REP, V11, P1097
3456789101112